

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 55921

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Efficacy and Safety of S-1 Maintenance Therapy in Advanced NSCLC Patients

Chun-Ling Mu *et al.* **therapy in advanced NSCLC patients**

Abstract

BACKGROUND

Previous reports demonstrated that S-1 has remarkable effects in the maintenance treatment of advanced non-small-cell lung cancer and less toxic and side effects than conventional drugs

AIM

To investigate the efficacy and safety of S-1 maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC).

METHODS

Ninety-four patients with non-small cell lung cancer admitted in our hospital from September 2015 to April 2018 were included in the study and divided into the S-1 group (47 cases) and the gemcitabine group (47 cases) by random digital table method. The S-1

Match Overview

1	Internet 50 words crawled on 01-May-2020 wclc2018.iaslc.org	2%
2	Internet 40 words crawled on 13-May-2020 worldwidescience.org	2%
3	Internet 39 words crawled on 25-Jul-2020 pesquisa.bvsalud.org	1%
4	Internet 31 words crawled on 04-Aug-2020 mafiadoc.com	1%
5	Crossref 29 words Tetsuro Yamashita, Yuji Ueda, Nobuaki Fuji, Tsuyoshi Itoh, Hideaki Kurioka, Tetsuhiko Shirasaka, Hisakazu Yamagish	1%
6	Internet 27 words crawled on 26-Jul-2020 www.semanticscholar.org	1%
7	Crossref 24 words "Abstracts", Journal of Thoracic Oncology, 2009	1%
8	Crossref 19 words Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohka wa et al. "Randomized Phase III Study of Gemcitabine Plu	1%



ALL IMAGES VIDEOS

341,000 Results Any time

A randomized phase 3 study of maintenance therapy with ...

<https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32987>

A randomized phase 3 study was performed to investigate the efficacy and safety of maintenance therapy with S-1 after induction therapy with carboplatin plus S-1 in patients with advanced squamous non-small cell lung cancer (NSCLC).

Author: Kaoru Tanaka, Satoshi Morita, Masahi... Publish Year: 2020

Switch maintenance chemotherapy using S-1 with or without ...

<https://www.ncbi.nlm.nih.gov/pubmed/28625650>

OBJECTIVES: We conducted this single-institute; prospective, non-randomized parallel two-arm phase II study to evaluate the efficacy and safety of switch maintenance chemotherapy with S-1 after induction therapy with a platinum-based regimen in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients not showing ...

Cited by: 6 Author: Seiji Niho, Yuichiro Ohe, Hironobu Ohmat...

Publish Year: 2017

Images of Study On the Efficacy and Safety of S-1 Maintenanc...

bing.com/images




Table 1. Efficacy and safety of maintenance with chemotherapy and targeted therapy in NSCLC patients

Author	Year	Phase	Regimen	OS	HR	95% CI	HR	95% CI
Chen et al	2017	Phase III	Carboplatin + paclitaxel + S-1 vs carboplatin + paclitaxel	18.1 vs 17.1 mo	0.95	0.79-1.14	0.95	0.79-1.14
Lee et al	2017	Phase III	Carboplatin + paclitaxel + S-1 vs carboplatin + paclitaxel	18.1 vs 17.1 mo	0.95	0.79-1.14	0.95	0.79-1.14
Chen et al	2017	Phase III	Carboplatin + paclitaxel + S-1 vs carboplatin + paclitaxel	18.1 vs 17.1 mo	0.95	0.79-1.14	0.95	0.79-1.14
Chen et al	2017	Phase III	Carboplatin + paclitaxel + S-1 vs carboplatin + paclitaxel	18.1 vs 17.1 mo	0.95	0.79-1.14	0.95	0.79-1.14

See all images >

Switch Maintenance Chemotherapy Using S-1 With or ...

<https://pubmed.ncbi.nlm.nih.gov/28625650>



ALL

IMAGES

VIDEOS

903,000 Results

Any time ▾

A randomized phase 3 study of maintenance therapy with S-1 ...

<https://pubmed.ncbi.nlm.nih.gov/32484914>

A randomized phase 3 study was performed to investigate the **efficacy and safety of maintenance therapy with S-1** after **induction therapy** with carboplatin plus S-1 in patients with **advanced squamous non-small cell lung cancer (NSCLC)**.

Author: Kaoru Tanaka, Satoshi Morita, Masahik... **Publish Year:** 2020

Switch Maintenance Chemotherapy Using S-1 With or Without ...

<https://pubmed.ncbi.nlm.nih.gov/28625650>

Switch maintenance chemotherapy with S-1 in combination with continuation **maintenance chemotherapy** with bevacizumab yielded modest **efficacy** with mild and acceptable toxicities. **Switch Maintenance Chemotherapy Using S-1 With or Without Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer: A Phase II Study**

Cited by: 6 **Author:** Seiji Niho, Yuichiro Ohe, Hironobu Ohmatsu...

Publish Year: 2017

A randomized phase 3 study of maintenance therapy with S-1 ...

<https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32987>

The most common toxicities during **maintenance therapy** with S-1 included anorexia, anemia, and fatigue, but most cases were not severe. Conclusions Continued **maintenance** with S-1 plus BSC is an **effective** and well-tolerated **treatment** option for patients with **advanced squamous NSCLC** previously treated with carboplatin plus S-1.

Author: Kaoru Tanaka, Satoshi Morita, Masahik... **Publish Year:** 2020



4,490,000 Results Any time ▾

[Switch Maintenance Chemotherapy Using S-1 With or Without ...](#)

<https://pubmed.ncbi.nlm.nih.gov/28625650>

Switch Maintenance Chemotherapy Using S-1 With or Without Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer: A Phase II Study. **Switch maintenance chemotherapy with S-1 in combination with continuation maintenance chemotherapy with bevacizumab yielded modest efficacy with mild and acceptable toxicities.**

Cited by: 6 **Author:** Seiji Niho, Yuichiro Ohe, Hironobu Ohmat...
Publish Year: 2017

[A randomized phase 3 study of maintenance therapy with S-1 ...](#)

<https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32987>

The most common toxicities during **maintenance therapy** with S-1 included anorexia, anemia, and fatigue, but most cases were not **severe**. **Conclusions.** Continued **maintenance** with S-1 plus BSC is an **effective** and well-tolerated **treatment** option for patients with **advanced squamous NSCLC** previously treated with carboplatin plus S-1.

Author: Kaoru Tanaka, Satoshi Morita, Masahi... **Publish Year:** 2020

[\[Efficacy and safety of gefitinib in maintenance therapy ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/18756941>

1. Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):221-4. [**Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer**].

Cited by: 4 **Author:** Wang Mz, Zhong W, Zhang L, Li Ly, Wan...
Publish Year: 2008

[Efficacy and safety of rh-endostatin \(Endostar\) combined ...](#)

<https://www.ncbi.nlm.nih.gov/pubmed/30152052>

Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. Zhou S(1), Zuo L(2), He X(1), Pi J(2), Jin J(2), Shi Y(1).

Author: Shengyu Zhou, Lijie Zuo, Xiaohui He, ... **Publish Year:** 2018